ArticleMicrobiology spectrum2025
Detection of serum anti-candidalysin IgG by indirect ELISA: a novel auxiliary tool for diagnosing invasive candidiasis in a preliminary pediatric study.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Overview of Risk Factors and Diagnosis of Invasive Candidiasis.Journal of fungi (Basel, Switzerland) · 2026Review
- Candidalysin at the epithelial-systemic interface: mechanistic evidence, critical-care relevance, and translational opportunities in invasive candidiasis.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Invasive candidiasis (IC) is the most common fungal infection in clinical settings, yet early diagnosis remains challenging. Candidalysin, a key virulence factor in invasive infections, exhibits site-specific pathogenicity. Our study identifies candidalysin as a serodominant antigenic peptide and reveals significantly elevated serum anti-candidalysin IgG levels in IC across diverse anatomical sites, suggesting its potential as a novel diagnostic biomarker. To evaluate this, we developed an indirect enzyme-linked immunosorbent assay (ELISA) to quantify serum anti-candidalysin IgG. The assay was validated in two distinct validation subsets using a 5-year cohort comprising 121 proven, probable, or possible IC cases from Hunan Children's Hospital, alongside 105 non-IC controls (patients with other infections and healthy individuals). In validation set 1, comparing proven IC cases (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.